Price T Rowe Associates Inc Century Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 14,882 shares of IPSC stock, worth $18,751. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,882
Previous 14,882
-0.0%
Holding current value
$18,751
Previous $38,000
31.58%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding IPSC
# of Institutions
67Shares Held
36.9MCall Options Held
8.7KPut Options Held
10.2K-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$6.82 Million1.66% of portfolio
-
Vr Adviser, LLC New York, NY5.39MShares$6.79 Million0.95% of portfolio
-
Boxer Capital, LLC San Diego, CA3.9MShares$4.91 Million0.35% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$4.05 Million0.43% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$3.65 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $74.2M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...